ARTICLE | Company News
Basilea submits MAA for isavuconazole
July 18, 2014 12:23 AM UTC
Basilea Pharmaceutica AG (SIX:BSLN) submitted an MAA to EMA for isavuconazole to treat invasive aspergillosis and invasive mucormycosis (zygomycosis). Partner Astellas Pharma Inc. (Tokyo:4503) submitt...